Table 2.

Clinical and immunohistochemical profile of patients with histologically confirmed extramedullary myeloma

Identifier		E1	E3#1	E8	E16	E17	E18#2
General	Age at dx	47	68	46	60	54	55
	Sex	m	m	m	m	m	m
	Subtype	λLC	IgGκ	IgGλ	IgGκ	IgAκ	IgGκ
	S&D at dx	IIIB	IA	IIIA	IIIA	IIIB	IIIA
	ISS at dx	2	1	ND	2	3	ND
	FISH	Normal	t(4;14), +1q21	ND	del13q14, del1p32, +1q21	del17p, t(4;14), del13q14, +1q21	Normal
	Previous lines of therapy	3	3	4	5	3	2
	Prior SCT, type (number)	Auto (2)	Auto (2)	Auto (1) allo (1)	Auto (2)	Auto (2)	Auto (3)
	Prior IMiDs	Len	Thal, Len	Len	Len, Pom	Len, Pom	None
	Prior PIs	Bort	Bort, Carf	Bort, Carf	Bort	Bort	Bort
	Prior mAbs	None	Dara	Dara	None	None	None
	EMD prior to elotuzumab	Yes	Yes	Yes	No	No	No
Elotuzumab treatment	Time from dx (months)	26	27	144	41	15	186
	Combination IMiD	Pom	Pom	Pom	Pom	Len, Pom	Len
	Treatment cycles	10	3	1	1	3	7
	Best response	PR	PR	PD	SD	SD	PR
	PFS (months)	9.4	2.9	1.3	0.9	2.7	9.0
	OS (months)	12.9	4.4	5.4	1.0	4.7	>9.8#3
	Type of progression	Serological + EMD	Serological + EMD	EMD	EMD	EMD	Serological + EMD
IHC	Localization of EMD	Paravertebral soft tissue	Skin	Paravertebral soft tissue	Maxillary mucosa	Lymph node	Thoracic wall
	SLAMF7 on CD138+ EM MM	+++#4	+++	+++	+++	+++	+++
	SLAMF7 on CD138+ BM MM	+++	+++	+++	+++	+++	+++

dx diagnosis; S&D Salmon&Durie; LC light chain; Ig immunoglobulin; ISS International Staging System; ND not done; FISH fluorescence in situ hybridization; SCT stem cell transplantation; auto autologous; allo allogeneic; IMiD immunomodulatory drug; Len lenalidomide; Thal thalidomide; Pom pomalidomide; PI proteasome inhibitor; Bort bortezomib; Carf carfilzomib; mAb monoclonal antibody; Dara daratumumab; EMD extramedullary disease; Elo elotuzumab; PR partial response; PD progressive disease; SD stable disease; PFS progression-free survival; OS overall survival; IHC immunohistochemistry; EM extramedullary; MM multiple myeloma; BM bone marrow

^#1Fig. 2

^#2Fig. 3

^#3Lost to follow-up

^#4Strong and consistent expression